Maze Therapeutics (NASDAQ:MAZE) Issues Earnings Results

Maze Therapeutics (NASDAQ:MAZE) announced its quarterly earnings results on Monday. The company reported ($0.79) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.78) by ($0.01), FiscalAI reports.

Maze Therapeutics Trading Up 0.1%

Shares of Maze Therapeutics stock traded up $0.05 on Tuesday, reaching $34.96. 10,251 shares of the company’s stock were exchanged, compared to its average volume of 669,120. The company has a market capitalization of $1.94 billion, a P/E ratio of -13.89 and a beta of 2.04. The firm’s 50-day moving average is $27.94 and its two-hundred day moving average is $31.72. The company has a debt-to-equity ratio of 0.09, a quick ratio of 18.31 and a current ratio of 18.31. Maze Therapeutics has a 52 week low of $21.95 and a 52 week high of $53.65.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on MAZE. Wall Street Zen cut Maze Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Maze Therapeutics in a report on Monday, September 21st. Citigroup started coverage on Maze Therapeutics in a research report on Wednesday, September 23rd. They issued a “buy” rating and a $50.00 price objective for the company. TD Cowen upgraded Maze Therapeutics to a “strong-buy” rating in a research report on Monday, August 24th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $46.00 target price on shares of Maze Therapeutics in a research note on Tuesday, September 22nd. Three equities research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $64.45.

Insider Buying and Selling at Maze Therapeutics

In related news, CEO Jason V. Coloma sold 34,501 shares of the business’s stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $26.29, for a total transaction of $907,031.29. Following the sale, the chief executive officer directly owned 18,151 shares in the company, valued at approximately $477,189.79. The trade was a 65.53% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CMO Harold Bernstein sold 16,142 shares of the stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $27.61, for a total value of $445,680.62. Following the completion of the transaction, the chief marketing officer directly owned 16,142 shares in the company, valued at approximately $445,680.62. This represents a 50.00% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 192,991 shares of company stock worth $5,187,559. Insiders own 5.30% of the company’s stock.

Hedge Funds Weigh In On Maze Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Bessemer Group Inc. lifted its position in Maze Therapeutics by 3.0% in the 3rd quarter. Bessemer Group Inc. now owns 496,253 shares of the company’s stock valued at $13,488,000 after acquiring an additional 14,463 shares in the last quarter. Jefferies Financial Group Inc. purchased a new stake in Maze Therapeutics in the 3rd quarter worth $1,519,000. Alps Advisors Inc. boosted its position in shares of Maze Therapeutics by 31.5% during the 3rd quarter. Alps Advisors Inc. now owns 73,574 shares of the company’s stock valued at $2,000,000 after acquiring an additional 17,604 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new stake in Maze Therapeutics during the third quarter worth approximately $77,000. Finally, Profund Advisors LLC raised its stake in shares of Maze Therapeutics by 410.5% in the third quarter. Profund Advisors LLC now owns 56,281 shares of the company’s stock valued at $1,530,000 after acquiring an additional 45,256 shares during the period.

Maze Therapeutics Company Profile

Maze Therapeutics is a clinical-stage biotechnology company developing precision medicines for people with serious diseases. Its research uses human genetics and functional genomics to identify disease-related biological pathways and potential drug targets.

The company’s Maze Compass platform is designed to connect genetic insights with biological research to guide drug discovery and development. Its investigational programs have included approaches for APOL1-mediated kidney disease and Pompe disease; these are not marketed treatments.

Founded in 2018, Maze is headquartered in South San Francisco, California.